Isavuconazole therapy protects immunosuppressed mice from mucormycosis. - Wikidata - awgldk - TriplyDB

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

http://www.wikidata.org/entity/Q39684037

about

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations Isavuconazole: A New Option for the Management of Invasive Fungal Infections.A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Our 2014 approach to mucormycosis.Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Isavuconazonium: first global approval.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Fungal Infections of the Central Nervous System in Children.Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.

P2860

Q26744049-272E4AA4-BCC7-4587-B8B5-2BEB7AB04569 Q28067726-A4A6C91B-7012-43D7-80C4-D3680D602A2B Q34474946-F6DD0C96-09C1-46C7-A054-D6CFCED00BF5 Q35076974-FE77F3E5-713C-4954-BB87-BCA1B3205332 Q35168889-A7A505F8-F5B3-482C-8BAA-756CA82B4E83 Q35385554-43D5D259-D560-40ED-B9EE-D32368A30A60 Q36290764-11109702-3B74-41CC-BDDE-260D82F60976 Q37096795-A595EC74-35F5-48E4-81AC-82D36E99052D Q37119937-2490EAEB-78E0-40FC-8182-4101CA297496 Q37203893-8A40F327-BF60-43E2-B3F8-F54900CAA954 Q38211830-BD8DEF19-6016-4AC9-B723-92571C969D3F Q38245046-238015A3-37B5-42F4-AFA1-A5E90FB185F3 Q38285488-65B70058-FCE7-45A3-8C63-20410B4092CD Q38436002-DA5C3E0B-2A4B-40B1-89E7-F7E16846729E Q38534865-B3CA1222-4578-4E4B-90AB-D7FD502BA687 Q38829932-0DB33EE3-9B77-4164-875D-622FFBEA282C Q38939506-C2147423-D435-4F7F-94A4-D5FB154223A6 Q38987096-42C7B399-9499-465E-9CCE-DF25267A32C0 Q39003715-C334CB60-8A0B-4EF7-B074-8BBBE4F4AFCA Q40043020-3A7AD837-2FD4-4AB6-A870-45113F456BAE Q40306219-0612A449-7CB5-4EF9-8761-BE44FAEC149F Q40474311-6214014C-5BFE-426E-A890-C461826CF1C3 Q40965373-851339AE-B0CE-4E59-B160-12FD6CC11CC2 Q46834709-4F07F443-53C0-4546-9AD2-5CACB7840902 Q47151374-0FA5929A-4816-46AB-A69C-A9DA9DE3E05B Q54214603-7739431C-84C1-4415-BEE1-D28A46D81147

P2860

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

http://www.wikidata.org/entity/Q39684037

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

@en

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

@nl

type

label

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

@en

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

@nl

prefLabel

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

@en

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

@nl

P1433

Q39684037-E7DE517F-C1DB-4723-8EFB-4E1B1EDB354A

P1476

Q39684037-E66FD13E-D46F-4832-88AB-43AF2EB8357C

P2093

Q39684037-6BAA4D1F-91DF-476D-BB19-02925E7017B6

Q39684037-A0CA600C-C882-4A71-BE15-0F3674B67F4F

Q39684037-DCD6193C-EC78-4921-B36E-D1F1D519D5C0

Q39684037-DD3E23CE-FB19-423B-AE24-6211F7D78BCF

Q39684037-E3397B88-FE00-4D63-89C1-400BDCE3930E

Q39684037-FC30F3F7-0A4A-4229-8BA0-999DF96D52F9

P2860

Q39684037-14106FA4-3909-4D1C-90D3-ED8A8AFBFFFF

Q39684037-15410C50-F71D-4DBD-AD20-625D56277043

Q39684037-1B7DF9B1-15FC-43C3-A93A-E06C46C65F0B

Q39684037-26E25193-5E49-41BB-97F1-09B3585B16BE

Q39684037-2889D897-C639-45BA-9A06-1A3A06B21B8E

Q39684037-29562D10-06C9-4ED2-9716-FE97537B2E01

Q39684037-34CC0B41-A177-4181-86E6-0860A815A10E

Q39684037-355A1519-11B7-4CA5-96E8-082EA1EB9417

Q39684037-43D7F359-D0C5-4643-9097-82B4117AC71F

Q39684037-50015A6B-FFCE-4F10-8B27-1F2C6990A127

P304

Q39684037-7EBD452A-DD1C-4EA8-BB14-F67F5628E903

P31

Q39684037-60EAC821-B9AF-4735-BDA1-5AF64B9E5D3F

P356

Q39684037-222C6B94-F97A-44D4-A2D4-9EAC34803779

P407

Q39684037-01D9CFB5-CBFC-40FB-98E8-01483B132560

P433

Q39684037-E436B06A-081C-40A3-91F7-0EF4D1C23728

P478

Q39684037-1105ABD0-FFE7-4D4A-B288-FAD9CF7D19B1

P577

Q39684037-CE55FD92-2FBB-4554-B96D-6225E56CD61F

P698

Q39684037-75F68CBC-636F-4377-AD8C-DB4FA2B919D6

P921

Q39684037-5FCD3C61-5128-4546-BCB5-2CFC00954F36

Q39684037-A51A321A-6FA2-4BAD-9FA4-04DDD5480021

P932

Q39684037-34B3356F-EEC8-47FB-A5D8-4E3C049EDF53

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

@en

P2093

Ashraf S Ibrahim

http://www.w3.org/2001/XMLSchema#string

Guanpingsheng Luo

http://www.w3.org/2001/XMLSchema#string

Hongkyu Lee

http://www.w3.org/2001/XMLSchema#string

John E Edwards

http://www.w3.org/2001/XMLSchema#string

Laura Kovanda

http://www.w3.org/2001/XMLSchema#string

Teclegiorgis Gebremariam

http://www.w3.org/2001/XMLSchema#string

P2860

Zygomycetes in human disease

Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.

Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate.

Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011.

Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern

Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

Improved outcome of zygomycosis in patients with hematological diseases?

Invasive mold infections following combat-related injuries

P304

2450-2453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02301-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24492363

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

isavuconazonium sulfate

P932

4023778

http://www.w3.org/2001/XMLSchema#string